CGP60474, a novel MITD1-targeted inhibitor for bladder cancer progression via CDK4/cyclin D1 pathway modulation
Targeted therapy holds promise for advanced bladder cancer, but its development is limited by a lack of therapeutic targets. Here, we show that MITD1 is elevated in bladder cancer and associated with poor patient prognosis. We find that MITD1 drives cancer progression by interacting with the CDK4/cyclin D1 complex to...